Neurocrine (NBIX)

NASDAQ:NBIX

NBIX

Neurocrine

RESEARCH TOOLSreports

Want to see NBIX full AI Analyst Report?

Neurocrine (NBIX) Stock Forecast & Price Target

1,573 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NBIX Analyst Ratings

Strong Buy

20 Buy

2 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Neurocrine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NBIX Stock 12 Month Forecast

Average Price Target

$183.00

▲(37.34% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is $183.00 with a high forecast of $242.00 and a low forecast of $140.00. The average price target represents a 37.34% change from the last price of $133.25.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"105":"$105","174":"$174","243":"$243","139.5":"$139.5","208.5":"$208.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":242,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$242.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":183,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$183.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$140.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[105,139.5,174,208.5,243],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.78,140.25846153846155,148.73692307692306,157.2153846153846,165.69384615384615,174.1723076923077,182.65076923076924,191.12923076923076,199.6076923076923,208.08615384615385,216.56461538461537,225.0430769230769,233.52153846153846,{"y":242,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.78,135.72,139.66,143.6,147.54,151.48,155.42000000000002,159.36,163.3,167.24,171.18,175.12,179.06,{"y":183,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.78,132.4123076923077,133.04461538461538,133.6769230769231,134.30923076923077,134.94153846153847,135.57384615384615,136.20615384615385,136.83846153846153,137.47076923076924,138.1030769230769,138.73538461538462,139.3676923076923,{"y":140,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":106.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.63,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.38,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.56,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.78,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$242.00

Average Price Target$183.00

Lowest Price Target$140.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ami Fadia

Needham

―

Buy

―

Reiterated

04/24/26

Needham Sticks to Its Buy Rating for Neurocrine (NBIX)

Sean Laaman

Morgan Stanley

$185

Hold

38.84%

Upside

Reiterated

04/20/26

Neurocrine Biosciences: Conservative VYKAT XR Outlook and Aggressive Margin Assumptions Justify Hold Rating

Tazeen Ahmad

Bank of America Securities

―

Buy

―

Reiterated

04/15/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Galmed Pharmaceuticals (NASDAQ: GLMD), Neurocrine (NASDAQ: NBIX) and Mesoblast (NASDAQ: MESO)

Andrew Fein

H.C. Wainwright

$192→$215

Buy

61.35%

Upside

Reiterated

04/07/26

Neurocrine price target raised to $215 from $192 at H.C. WainwrightNeurocrine price target raised to $215 from $192 at H.C. Wainwright

Laura Chico

Wedbush

$151→$166

Buy

24.58%

Upside

Reiterated

04/07/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Centene (NYSE: CNC)

Akash Tewari

Jefferies

$172

Buy

29.08%

Upside

Reiterated

04/07/26

Jefferies Reaffirms Their Buy Rating on Neurocrine (NBIX)

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

04/07/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Bausch + Lomb Corporation (NYSE: BLCO) and UnitedHealth (NYSE: UNH)

Brian Abrahams

RBC Capital

$177→$176

Buy

32.08%

Upside

Reiterated

04/07/26

Neurocrine price target lowered to $176 from $177 at RBC CapitalNeurocrine price target lowered to $176 from $177 at RBC Capital

Sumant Kulkarni

Canaccord Genuity

$164→$200

Buy

50.09%

Upside

Reiterated

04/07/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Guardant Health (NASDAQ: GH) and Compass Therapeutics (NASDAQ: CMPX)

Myles Minter

William Blair

―

Buy

―

Reiterated

04/06/26

Analysts Conflicted on These Healthcare Names: Oncolytics Biotech (NASDAQ: ONCY) and Neurocrine (NASDAQ: NBIX)

Rudy Li

Wolfe Research

$160

Buy

20.08%

Upside

Reiterated

04/06/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Theravance Biopharma (NASDAQ: TBPH)

Evan Seigerman

BMO Capital

$131.6→$140

Hold

5.07%

Upside

Assigned

04/06/26

Balanced View on Neurocrine Biosciences: Favorable Soleno Acquisition Prospects Offset by Long-Term Ingrezza and Orphan Market Execution Risks

Ashwani Verma

UBS

$161

Buy

20.83%

Upside

Reiterated

04/06/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Yigal Nochomovitz

Citi

$204→$242

Buy

81.61%

Upside

Assigned

04/06/26

Neurocrine price target raised to $242 from $204 at CitiNeurocrine price target raised to $242 from $204 at Citi

Anupam Rama

J.P. Morgan

$176→$177

Buy

32.83%

Upside

Assigned

03/12/26

Neurocrine price target raised to $177 from $176 at JPMorganNeurocrine price target raised to $177 from $176 at JPMorgan

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ami Fadia

Needham

―

Buy

―

Reiterated

04/24/26

Needham Sticks to Its Buy Rating for Neurocrine (NBIX)

Sean Laaman

Morgan Stanley

$185

Hold

38.84%

Upside

Reiterated

04/20/26

Neurocrine Biosciences: Conservative VYKAT XR Outlook and Aggressive Margin Assumptions Justify Hold Rating

Tazeen Ahmad

Bank of America Securities

―

Buy

―

Reiterated

04/15/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Galmed Pharmaceuticals (NASDAQ: GLMD), Neurocrine (NASDAQ: NBIX) and Mesoblast (NASDAQ: MESO)

Andrew Fein

H.C. Wainwright

$192→$215

Buy

61.35%

Upside

Reiterated

04/07/26

Neurocrine price target raised to $215 from $192 at H.C. WainwrightNeurocrine price target raised to $215 from $192 at H.C. Wainwright

Laura Chico

Wedbush

$151→$166

Buy

24.58%

Upside

Reiterated

04/07/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Centene (NYSE: CNC)

Akash Tewari

Jefferies

$172

Buy

29.08%

Upside

Reiterated

04/07/26

Jefferies Reaffirms Their Buy Rating on Neurocrine (NBIX)

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

04/07/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Bausch + Lomb Corporation (NYSE: BLCO) and UnitedHealth (NYSE: UNH)

Brian Abrahams

RBC Capital

$177→$176

Buy

32.08%

Upside

Reiterated

04/07/26

Neurocrine price target lowered to $176 from $177 at RBC CapitalNeurocrine price target lowered to $176 from $177 at RBC Capital

Sumant Kulkarni

Canaccord Genuity

$164→$200

Buy

50.09%

Upside

Reiterated

04/07/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Guardant Health (NASDAQ: GH) and Compass Therapeutics (NASDAQ: CMPX)

Myles Minter

William Blair

―

Buy

―

Reiterated

04/06/26

Analysts Conflicted on These Healthcare Names: Oncolytics Biotech (NASDAQ: ONCY) and Neurocrine (NASDAQ: NBIX)

Rudy Li

Wolfe Research

$160

Buy

20.08%

Upside

Reiterated

04/06/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Theravance Biopharma (NASDAQ: TBPH)

Evan Seigerman

BMO Capital

$131.6→$140

Hold

5.07%

Upside

Assigned

04/06/26

Balanced View on Neurocrine Biosciences: Favorable Soleno Acquisition Prospects Offset by Long-Term Ingrezza and Orphan Market Execution Risks

Ashwani Verma

UBS

$161

Buy

20.83%

Upside

Reiterated

04/06/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Yigal Nochomovitz

Citi

$204→$242

Buy

81.61%

Upside

Assigned

04/06/26

Neurocrine price target raised to $242 from $204 at CitiNeurocrine price target raised to $242 from $204 at Citi

Anupam Rama

J.P. Morgan

$176→$177

Buy

32.83%

Upside

Assigned

03/12/26

Neurocrine price target raised to $177 from $176 at JPMorganNeurocrine price target raised to $177 from $176 at JPMorgan

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

3 Months

xxx

Success Rate

17/26 ratings generated profit

Average Return

+3.16%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.38% of your transactions generating a profit, with an average return of +3.16% per trade.

1 Year

Laura ChicoWedbush

Success Rate

15/22 ratings generated profit

Average Return

+3.41%

Copying Laura Chico's trades and holding each position for 1 Year would result in 68.18% of your transactions generating a profit, with an average return of +3.41% per trade.

2 Years

xxx

Success Rate

20/28 ratings generated profit

Average Return

+15.26%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +15.26% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NBIX Analyst Recommendation Trends

Rating

Jan 26

Feb 26

Mar 26

Apr 26

May 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NBIX has received 15 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NBIX average Analyst price target in the past 3 months is 183.00.

Each month's total comprises the sum of three months' worth of ratings.

NBIX Financial Forecast

NBIX Earnings Forecast

Currently, no earnings data available.

NBIX Sales Forecast

Currently, no sales data available.

NBIX Stock Forecast FAQ

What is NBIX’s average 12-month price target, according to analysts?

Based on analyst ratings, Neurocrine’s 12-month average price target is 183.00.

What is NBIX’s upside potential, based on the analysts’ average price target?

Neurocrine has 37.34% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NBIX a Buy, Sell or Hold?

Neurocrine has a consensus rating of Strong Buy which is based on 20 buy ratings, 2 hold ratings and 0 sell ratings.

What is Neurocrine’s price target?

The average price target for Neurocrine is 183.00. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $242.00 ,the lowest forecast is $140.00. The average price target represents 37.34% Increase from the current price of $133.25.

What do analysts say about Neurocrine?

Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of NBIX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Neurocrine (NBIX) Stock Forecast & Price Target

NBIX Analyst Ratings

NBIX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Neurocrine

NBIX Analyst Recommendation Trends

NBIX Financial Forecast

NBIX Earnings Forecast

NBIX Sales Forecast

NBIX Stock Forecast FAQ

Detailed List of Analyst Forecasts